Literature DB >> 33063786

ONS Guidelines™ for Opioid-Induced and Non-Opioid-Related Cancer Constipation.

Barbara Rogers1, Pamela K Ginex2, Allison Anbari3, Brian J Hanson4, Kristine B LeFebvre2, Rachael Lopez5, Deborah M Thorpe6, Brenda Wolles7, Kerri A Moriarty2, Christine Maloney, Mark Vrabel2, Rebecca L Morgan8.   

Abstract

PURPOSE: This evidence-based guideline intends to support clinicians, patients, and others in decisions regarding the treatment of constipation in patients with cancer. METHODOLOGIC APPROACH: An interprofessional panel of healthcare professionals with patient representation prioritized clinical questions and patient outcomes for the management of cancer-related constipation. Systematic reviews of the literature were conducted. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was used to assess the evidence and make recommendations.
FINDINGS: The panel agreed on 13 recommendations for the management of opioid-induced and non-opioid-related constipation in patients with cancer. IMPLICATIONS FOR NURSING: The panel conditionally recommended a bowel regimen in addition to lifestyle education as first-line treatment for constipation. For patients starting opioids, the panel suggests a bowel regimen as prophylaxis. Pharmaceutical interventions are available and recommended if a bowel regimen has failed. Acupuncture and electroacupuncture for non-opioid-related constipation are recommended in the context of a clinical trial. SUPPLEMENTARY MATERIAL CAN BE FOUND AT HTTPS: //bit.ly/30y29sI.

Entities:  

Keywords:  GRADE; acupuncture; cancer; constipation; guideline; opioid-induced constipation

Year:  2020        PMID: 33063786     DOI: 10.1188/20.ONF.671-691

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  1 in total

1.  Risk and main contributing factors for constipation in patients with gastrointestinal cancer: a multicenter cross-sectional study in China.

Authors:  Xiaoxiao Ma; Qian Lu; Yuhan Lu; Xin Li
Journal:  Support Care Cancer       Date:  2022-07-02       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.